Roche during the first nine months of 2026, Roche Group sales advanced 6% at constant exchange rates (CER)¹, 1% in Swiss francs and 7% in US dollars², supported by demand for innovative medicines and ...
Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of ...
A critical review finds that immunohistochemical injury timelines established in ventricular muscle cannot yet be reliably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results